Over the past couple of years, drug makers have increasingly explored outcomes-based contracting as a way to convince payers to cover their medicines. Basically, this notion revolves around the idea that an insurer will get a drug at a lower cost if a patient does not benefit as planned. But not all deals are likely to deliver, and a new analysis argued that an agreement offered by Amgen (AMGN) is a notable example.

To wit, Amgen sells Repatha, a new type of cholesterol medicine approved in 2015 to treat patients who struggle to control cholesterol using statins, particularly those with an inherited disorder known as familial hypercholesterolemia. Around the same time, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) won regulatory approval to market a competing treatment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy